As an investment manager and by using its InnoCom Bio Equities Fund I and Fund II, InnoCom Bio Equities, Inc. is able to provide three services to the Life Sciences company in the difficult transition between grant funding and big pharma licensed or IPO funded success: each of its founders sits on the Board and assumes a C-Level role to assist the emerging scientist with Infrastructure Development & Maintenance, CEO Advisory, and Capital Introductions in the $10 to $35 million range. Additional capital is available if justified and necessary.
California Life Sciences members receive 10% discount on services.